Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AQST Aquestive Therapeutics	$4.05 +7.0%	$3.73	$2.12 ▼ $5.80	$400.79M	1.99	1.49 million shs	975,451 shs
FBRX Forte Biosciences	$10.51 -2.4%	$11.46	$4.11 ▼ $28.68	$69.91M	2.91	62,841 shs	9,198 shs
MBX MBX Biosciences	$13.12 +4.7%	$12.13	$4.81 ▼ $27.50	$443.37M	N/A	325,268 shs	254,229 shs
TERN Terns Pharmaceuticals	$6.51 -0.3%	$4.81	$1.87 ▼ $11.40	$568.38M	-0.05	1.16 million shs	780,143 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AQST Aquestive Therapeutics	-2.07%	-4.06%	-5.74%	+70.27%	+11.18%
FBRX Forte Biosciences	+2.38%	+10.93%	+1.99%	+41.58%	+64,039.25%
MBX MBX Biosciences	+11.28%	+4.85%	-3.91%	+23.21%	+1,252,999,900.00%
TERN Terns Pharmaceuticals	+3.65%	+7.40%	+33.27%	+134.89%	-0.61%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AQST Aquestive Therapeutics	1.9798 of 5 stars	3.5	3.0	0.0	3.0	0.0	0.0
FBRX Forte Biosciences	3.1673 of 5 stars	3.5	5.0	0.0	2.0	1.7	0.6
MBX MBX Biosciences	2.5626 of 5 stars	3.5	0.0	0.0	3.1	1.7	0.6
TERN Terns Pharmaceuticals	4.017 of 5 stars	3.3	2.0	4.1	2.6	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AQST Aquestive Therapeutics	3.00	Buy	$10.14	150.75% Upside
FBRX Forte Biosciences	3.00	Buy	$61.00	480.62% Upside
MBX MBX Biosciences	3.00	Buy	$37.63	186.82% Upside
TERN Terns Pharmaceuticals	2.60	Moderate Buy	$15.63	140.02% Upside

Current Analyst Ratings Breakdown

Latest FBRX, AQST, MBX, and TERN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/5/2025	MBX MBX Biosciences	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$38.00
7/16/2025	MBX MBX Biosciences	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$38.00
6/24/2025	FBRX Forte Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$61.00
6/17/2025	AQST Aquestive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/2/2025	AQST Aquestive Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$7.00
5/15/2025	AQST Aquestive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
5/13/2025	TERN Terns Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$26.00 ➝ $15.00

(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AQST Aquestive Therapeutics	$44.13M	9.10	N/A	N/A	($0.66) per share	-6.13
FBRX Forte Biosciences	N/A	N/A	N/A	N/A	$8.21 per share	N/A
MBX MBX Biosciences	N/A	N/A	N/A	N/A	N/A	N/A
TERN Terns Pharmaceuticals	N/A	N/A	N/A	N/A	$3.49 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AQST Aquestive Therapeutics	-$44.14M	-$0.70	N/A	N/A	N/A	-147.38%	N/A	-62.22%	N/A
FBRX Forte Biosciences	-$35.48M	-$16.29	N/A	N/A	N/A	N/A	-149.15%	-114.25%	8/13/2025 (Estimated)
MBX MBX Biosciences	N/A	-$4.54	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TERN Terns Pharmaceuticals	-$88.85M	-$1.04	N/A	N/A	N/A	N/A	-27.35%	-26.18%	N/A

Latest FBRX, AQST, MBX, and TERN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	FBRX Forte Biosciences	-$1.21	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	AQST Aquestive Therapeutics	-$0.18	-$0.14	+$0.04	-$0.14	$11.32 million	$10.00 million
8/5/2025	Q2 2025	TERN Terns Pharmaceuticals	-$0.28	-$0.26	+$0.02	-$0.26	N/A	N/A
5/15/2025	Q1 2025	FBRX Forte Biosciences	-$0.89	-$1.37	-$0.48	-$1.37	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AQST Aquestive Therapeutics	N/A	N/A	N/A	N/A	N/A
FBRX Forte Biosciences	N/A	N/A	N/A	N/A	N/A
MBX MBX Biosciences	N/A	N/A	N/A	N/A	N/A
TERN Terns Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AQST Aquestive Therapeutics	N/A	4.87	4.48
FBRX Forte Biosciences	N/A	5.22	5.22
MBX MBX Biosciences	N/A	N/A	N/A
TERN Terns Pharmaceuticals	N/A	24.70	24.70

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AQST Aquestive Therapeutics	32.45%
FBRX Forte Biosciences	77.63%
MBX MBX Biosciences	N/A
TERN Terns Pharmaceuticals	98.26%

Insider Ownership

Company	Insider Ownership
AQST Aquestive Therapeutics	7.85%
FBRX Forte Biosciences	5.90%
MBX MBX Biosciences	52.19%
TERN Terns Pharmaceuticals	1.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AQST Aquestive Therapeutics	160	99.33 million	91.53 million	Optionable
FBRX Forte Biosciences	5	6.58 million	6.20 million	Optionable
MBX MBX Biosciences	36	33.59 million	N/A	N/A
TERN Terns Pharmaceuticals	40	87.51 million	86.20 million	Not Optionable

FBRX, AQST, MBX, and TERN Headlines

Recent News About These Companies

5 Oral Obesity Drugs Challenging Lilly’s Orforglipron

August 12 at 2:18 AM | biospace.comB

William Blair Has Positive Outlook of TERN FY2025 Earnings

August 9, 2025 | marketbeat.com

Terns Pharmaceuticals (NASDAQ:TERN) Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPS

August 6, 2025 | marketbeat.com

Terns Seeks Partners for Metabolic Assets Amid Oversaturated Obesity Market

August 6, 2025 | biospace.comB

Terns to stop funding metabolic disease trials beyond 2025, seeks partners for assets

August 6, 2025 | fiercebiotech.comF

Terns (TERN) Q2 Net Loss Narrows 16%

August 6, 2025 | fool.com

Brokerages Set Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Target Price at $15.63

August 6, 2025 | americanbankingnews.com

Terns Pharmaceuticals Reports Q2 2025 Financial Results

August 6, 2025 | tipranks.com

Terns Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

August 5, 2025 | globenewswire.com

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

August 4, 2025 | globenewswire.com

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Given Consensus Recommendation of "Moderate Buy" by Brokerages

August 3, 2025 | marketbeat.com

Terns Pharmaceuticals (TERN) to Release Earnings on Monday

August 3, 2025 | americanbankingnews.com

Terns Pharmaceuticals (TERN) to Release Quarterly Earnings on Monday

July 28, 2025 | marketbeat.com

Obesity in Focus: ADA Reveals R&D Priorities for Blockbusters-in-Waiting

July 14, 2025 | biospace.comB

Terns Pharmaceuticals CEO & Director Acquires 98% More Stock

July 4, 2025 | finance.yahoo.com

Terns pharmaceuticals CEO Burroughs buys $90k in shares

June 27, 2025 | investing.com

Rivus' weight loss drug scores MASH phase 2 win, showcases muscle-sparing potential

June 26, 2025 | fiercebiotech.comF

Terns Pharmaceuticals Presents Promising Phase 1 Data for TERN-601 at ADA 2025 and Completes Enrollment for Phase 2 FALCON Trial - Nasdaq

June 24, 2025 | nasdaq.com

Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American ... - Morningstar

June 24, 2025 | morningstar.comM

Novel GLP-1/GIP Agent Led to Weight Loss With Once-Monthly Dosing

June 23, 2025 | medpagetoday.comM

Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions

June 23, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBRX, AQST, MBX, and TERN Company Descriptions

Aquestive Therapeutics NASDAQ:AQST

$4.04 +0.27 (+7.01%)

As of 02:45 PM Eastern

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Forte Biosciences NASDAQ:FBRX

$10.51 -0.25 (-2.36%)

As of 02:40 PM Eastern

Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

MBX Biosciences NYSE:MBX

$13.12 +0.59 (+4.67%)

As of 02:44 PM Eastern

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.

Terns Pharmaceuticals NASDAQ:TERN

$6.51 -0.02 (-0.31%)

As of 02:44 PM Eastern

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time